Bacteriophages : Alternatives to Antibiotics and Beyond

There is talk of an upcoming antibiotic armageddon, with untreatable post-operative infections, and similarly untreatable complications after chemotherapy. Indeed, the now famous “O’Neill Report” (https://amr-review.org/) suggests that, by 2050, more people might die from antibiotic-resistant bacter...

Full description

Saved in:
Bibliographic Details
HerausgeberIn:
Sonstige:
Year of Publication:2020
Language:English
Physical Description:1 electronic resource (390 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 05600nam-a2201477z--4500
001 993546336004498
005 20240122104458.0
006 m o d
007 cr|mn|---annan
008 202105s2020 xx |||||o ||| 0|eng d
035 |a (CKB)5400000000045038 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/69333 
035 |a (EXLCZ)995400000000045038 
041 0 |a eng 
100 1 |a Suárez, Pilar García  |4 edt 
245 1 0 |a Bacteriophages  |b Alternatives to Antibiotics and Beyond 
246 |a Bacteriophages 
260 |a Basel, Switzerland  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2020 
300 |a 1 electronic resource (390 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a There is talk of an upcoming antibiotic armageddon, with untreatable post-operative infections, and similarly untreatable complications after chemotherapy. Indeed, the now famous “O’Neill Report” (https://amr-review.org/) suggests that, by 2050, more people might die from antibiotic-resistant bacterial infections than from cancer. While we are still learning all the subtle drivers of antibiotic resistance, it seems increasingly clear that we need to take a “one health” approach, curtailing the use of antibiotics in both human and veterinary medicine. However, there are no new classes of antibiotics on our horizon. Maybe something that has been around “forever” can come to our rescue—bacteriophages! Nevertheless, it is also necessary to do things differently, and use these new antimicrobials appropriately. Therefore, an in-depth study of bacteriophage biology and case-by-case applications might be required. Whilst by no means comprehensive, this book does cover some of the many topics related to bacteriophages as antimicrobials, including their use in human therapy and aquaculture. It also explores the potential use of phage endolysins as substitutes of antibiotics in two sectors where there is an urgent need—human therapy and the agro-food industry. Last but not least, there is an excellent perspective article on phage therapy implementation. 
546 |a English 
650 7 |a Medicine  |2 bicssc 
653 |a bacteriophages 
653 |a dairy industry 
653 |a pathogens 
653 |a lactic acid bacteria 
653 |a fermentation failure 
653 |a biofilms 
653 |a antimicrobial resistance 
653 |a antimicrobials 
653 |a lysins 
653 |a horizontal gene transfer, transduction 
653 |a biofilm 
653 |a phage therapy 
653 |a resistance 
653 |a bacteriophage 
653 |a models 
653 |a agent based 
653 |a mass action 
653 |a bacterial phage resistance 
653 |a regression modeling 
653 |a MRSA 
653 |a Clostridium difficile 
653 |a Clostridium difficile infection 
653 |a microbiome 
653 |a in vitro fermentation model 
653 |a marine vibrios 
653 |a biological control 
653 |a aquaculture 
653 |a interactions 
653 |a vibriosis 
653 |a Aeromonas hydrophila 
653 |a Motile Aeromonas Septicemia 
653 |a MAS 
653 |a multiple-antibiotic-resistance 
653 |a striped catfish (Pangasianodon hypophthalmus) 
653 |a endolysin 
653 |a antibiotics 
653 |a one health 
653 |a protein engineering 
653 |a Aeromonas salmonicida 
653 |a furunculosis 
653 |a phage-resistant mutants 
653 |a proteins 
653 |a infrared spectroscopy 
653 |a lysin 
653 |a lytic enzyme 
653 |a peptidoglycan hydrolase 
653 |a antimicrobial 
653 |a antibacterial 
653 |a antibiotic resistance 
653 |a bacteriophage therapy 
653 |a Nagoya Protocol 
653 |a CRISPR CAS 
653 |a phage isolation 
653 |a phage resistance 
653 |a Staphylococcus 
653 |a Kayvirus 
653 |a Vibrio anguillarum 
653 |a fish larvae 
653 |a challenge trials 
653 |a phage display 
653 |a enzybiotics 
653 |a Bacteriophages 
653 |a diabetic foot ulcer 
653 |a osteomyelitis 
653 |a Staphylococcus aureus 
653 |a Antibiotic-resistant bacteria 
653 |a lysogenic conversion 
653 |a prophage induction 
653 |a read recruitment 
653 |a shiga toxin 
653 |a American Foulbrood 
653 |a phage 
653 |a Paenibacillus larvae 
653 |a Brevibacillus laterosporus 
653 |a treatment 
653 |a safety 
653 |a bystander phage therapy 
653 |a Mycobacterium smegmatis 
653 |a mycobacteriophages 
653 |a directed evolution 
653 |a PlyC CHAP 
653 |a protein net charge 
653 |a CBD-independent 
653 |a FoldX 
653 |a STEC-specific bacteriophage 
653 |a whole genome sequencing 
653 |a STEC O145 strains 
653 |a antimicrobial agent 
653 |a Pseudomonas aeruginosa 
653 |a dual-species 
653 |a antibiotic 
653 |a synergy 
653 |a simultaneous 
653 |a sequential 
653 |a microbiome therapy 
653 |a evolution 
776 |z 3-03943-404-7 
776 |z 3-03943-405-5 
700 1 |a Fernández, Lucía  |4 edt 
700 1 |a Suárez, Pilar García  |4 oth 
700 1 |a Fernández, Lucía  |4 oth 
906 |a BOOK 
ADM |b 2024-01-23 00:50:11 Europe/Vienna  |f system  |c marc21  |a 2022-04-04 09:22:53 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338233260004498&Force_direct=true  |Z 5338233260004498  |b Available  |8 5338233260004498